A nonrandomized, single-arm, phase 2 prospective trial enrolled patients with inoperable, stage III EGFR-mutant NSCLC who received osimertinib 80 mg daily for 12 weeks. This evidence concerns the gene EGFR and non-small cell lung carcinoma.